The work considered 70 unresectable stage III–IV melanoma patients undergoing baseline 18F-FDG PET/CT; these were assigned to the BRAFV600 (35 patients, 100 lesions) or BRAF wild-type group (35 patients, 79 lesions) according to the mutational status. The gene discussed is BRAF; the disease is melanoma.